Those who then substituted sorafenib to anti-VEGF siRNA, load current combination with the targeting liposomes delegated authority vessel density and inhibited tumor growth, and prevented TAM from infiltration into the cancer cell (McCallion et al., 2019). The gene discussed is VEGFA; the disease is neoplasm.